To investigate clinical efficacy and safety of roxadustat on renal anemia in elderly patients with non-dialysis chronic kidney disease (NDD-CKD). Methods:NDD-CKD patients (age≥65 years) treated with roxadustat were en-rolled. The changes of laboratory parameters before and after roxadustat treatment were analyzed retrospectively. Results:(1)A total of fifty-eight patients were included in this study with an average age of 76. 0(69.0,83.0) years old. After 3 months of treatment,Hb,RBC and HCT increased significantly (P<0.001);SF decreased significantly (P<0.05),TIBC increased significantly (P<0.05),but TSAT and SI did not change significantly (P>0.05). (2)The mean change from baseline in Hb level and Hb response rate in iron supplementation group were significantly higher than those in non-iron supplementation group (P<0.05). (3)There was no significant difference in serum potassium level and incidence of hyperkalemia before and after treatment (P>0.05). Conclu-sion:Low-dose roxadustat significantly improved renal anemia in elderly patients with NDD-CKD,while oral iron therapy helped to correct the anemia. Roxadustat did not increase the incidence of hyperkalemia.
维普
万方数据